- BioCorRx's (OTCQB:BICX) R&D subsidiary, BioCorRx Pharmaceuticals, has acquired a portfolio of six Therakine Biodelivery GmbH patent families that broadly cover sustained release delivery platforms for the local delivery of biologic and small molecule drugs.
- The portfolio includes issued patents and several pending patent applications which relate to BICX101.
- Additional patent applications have also been filed in the U.S. and in Europe that would further strengthen BioCorRx’s intellectual property position if granted.